A RANDOMIZED, DOUBLE-BLIND, MULTIPLE ASCENDING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PCO371 IN PATIENTS WITH HYPOPARATHYROIDISM

Registry ID

PCO104UG

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

CHUGAI PHARMACEUTICAL CO LTD

Start date

2020-04-20

Last update

2020-04-20

Conditions

• HYPOPARATHYROIDISM

Related clinical trials

• A PHASE 3 MULTI CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ENEBOPARATIDE (AZP3601), A PARATHYROID HORMONE RECEPTOR AGONIST, IN PATIENTS WITH CHRONIC HYPOPARATHYROIDISM (CALYPSO)
• OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO ASSESS THE PK AND PD PROFILES OF ONCE-DAILY AND TWICE-DAILY DOSE REGIMENS OF RECOMBINANT HUMAN PARATHYROID HORMONE (RHPTH[1-83]) ADMINISTERED SUBCUTANEOUSLY TO SUBJECTS WITH HYPOPARATHYROIDISM

View on source registry